Top

European Journal of Nuclear Medicine and Molecular Imaging

Published in:

01-07-2020 | Metastasis | Original Article

Comparison of [⁶⁸Ga]Ga-DOTA-FAPI-04 and [¹⁸F] FDG PET/CT for the diagnosis of primary and metastatic lesions in patients with various types of cancer

Authors: Haojun Chen, Yizhen Pang, Jingxun Wu, Liang Zhao, Bing Hao, Jing Wu, Jihong Wei, Siming Wu, Long Zhao, Zuoming Luo, Xuehua Lin, Chengrong Xie, Long Sun, Qin Lin, Hua Wu

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 8/2020

Abstract

Purpose

We evaluated the potential usefulness of [⁶⁸Ga]Ga-DOTA-FAPI-04 positron emission tomography/computed tomography (PET/CT) for the diagnosis of primary and metastatic lesions in various types of cancer, compared with [¹⁸F] FDG PET/CT.

Methods

A total of 75 patients with various types of cancer underwent contemporaneous [⁶⁸Ga]Ga-DOTA-FAPI-04 and [¹⁸F] FDG PET/CT either for an initial assessment or for recurrence detection. Tumour uptake was quantified by the maximum standard uptake value (SUV_max). The sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) and accuracy of [¹⁸F] FDG and [⁶⁸Ga]Ga-DOTA-FAPI-04 PET/CT were calculated and compared to evaluate the diagnostic efficacy.

Results

The study cohort consisted of 75 patients (47 males and 28 females; median age, 61.5 years; age range, 32–85 years). Fifty-four patients with 12 different tumour entities underwent paired [⁶⁸Ga]Ga-DOTA-FAPI-04 and [¹⁸F] FDG PET/CT for initial assessment, while the other 21 patients underwent paired scans for recurrence detection. [⁶⁸Ga]Ga-DOTA-FAPI-04 PET/CT was able to clearly identify 12 types of malignant tumours with favourable tumour-to-background contrast, which resulted in a higher detection rate of primary tumours than did [¹⁸F] FDG PET/CT (98.2% vs. 82.1%, P = 0.021). Meanwhile, [⁶⁸Ga]Ga-DOTA-FAPI-04 PET/CT showed a better sensitivity than [¹⁸F] FDG PET/CT in the detection of lymph nodes (86.4% vs. 45.5%, P = 0.004) and bone and visceral metastases (83.8% vs. 59.5%, P = 0.004).

Conclusion

[⁶⁸Ga]Ga-DOTA-FAPI-04 PET/CT showed a superior diagnostic efficacy than [¹⁸F] FDG PET/CT for the diagnosis of primary and metastatic lesions in patients with various types of cancer, especially in identifying liver metastases, peritoneal carcinomatosis, and brain tumours.

Available only for authorised users

Garin-Chesa P, Old LJ, Rettig WJ. Cell surface glycoprotein of reactive stromal fibroblasts as a potential antibody target in human epithelial cancers. Proc Natl Acad Sci U S A. 1990;1990(87):7235–9.CrossRef

Hamson EJ, Keane FM, Tholen S, Schilling O, Gorrell MD. Understanding fibroblast activation protein (FAP): substrates, activities, expression and targeting for cancer therapy. Proteomics Clin Appl. 2014;8(5–6):454–63. https://doi.org/10.1002/prca.201300095.CrossRefPubMed

Siveke JT. Fibroblast-activating protein: targeting the roots of the tumor microenvironment. J Nucl Med. 2018;59(9):1412–4. https://doi.org/10.2967/jnumed.118.214361.CrossRefPubMed

Cohen SJ, Alpaugh RK, Palazzo I, Meropol NJ, Rogatko A, Xu Z, et al. Fibroblast activation protein and its relationship to clinical outcome in pancreatic adenocarcinoma. Pancreas. 2008;37(2):154–8. https://doi.org/10.1097/MPA.0b013e31816618ce.CrossRefPubMed

Zhang Y, Tang H, Cai J, Zhang T, Guo J, Feng D, et al. Ovarian cancer-associated fibroblasts contribute to epithelial ovarian carcinoma metastasis by promoting angiogenesis, lymphangiogenesis and tumor cell invasion. Cancer Lett. 2011;303(1):47–55. https://doi.org/10.1016/j.canlet.2011.01.011.CrossRefPubMed

Ju M-J, Qiu S-J, Fan J, Xiao Y-S, Gao Q, Zhou J, et al. Peritumoral activated hepatic stellate cells predict poor clinical outcome in hepatocellular carcinoma after curative resection. Am J Clin Pathol. 2009;131(4):498–510.CrossRefPubMed

Wikberg ML, Edin S, Lundberg IV, Biology BVGJT. High intratumoral expression of fibroblast activation protein (FAP) in colon cancer is associated with poorer patient prognosis. Tumor Biol. 2013;34(2):1013–20.CrossRef

Rettig WJ, Su SL, Fortunato SR, Scanlan MJ, Raj BKM, Garin-Chesa P, et al. Fibroblast activation protein: purification, epitope mapping and induction by growth factors. Int J Cancer. 1994;58(3):385–92.CrossRefPubMed

Loktev A, Lindner T, Mier W, Debus J, Altmann A, Jager D, et al. A tumor-imaging method targeting cancer-associated fibroblasts. J Nucl Med. 2018;59(9):1423–9. https://doi.org/10.2967/jnumed.118.210435.CrossRefPubMedPubMedCentral

10.

Lindner T, Loktev A, Altmann A, Giesel F, Kratochwil C, Debus J, et al. Development of quinoline-based theranostic ligands for the targeting of fibroblast activation protein. J Nucl Med. 2018;59(9):1415–22. https://doi.org/10.2967/jnumed.118.210443.CrossRefPubMed

11.

Giesel FL, Kratochwil C, Lindner T, Marschalek MM, Loktev A, Lehnert W, et al. ⁶⁸Ga-FAPI PET/CT: biodistribution and preliminary dosimetry estimate of 2 DOTA-containing FAP-targeting agents in patients with various cancers. J Nucl Med. 2019;60(3):386–92. https://doi.org/10.2967/jnumed.118.215913.CrossRefPubMedPubMedCentral

12.

Kratochwil C, Flechsig P, Lindner T, Abderrahim L, Altmann A, Mier W, et al. ⁶⁸Ga-FAPI PET/CT: tracer uptake in 28 different kinds of cancer. J Nucl Med. 2019;60(6):801–5. https://doi.org/10.2967/jnumed.119.227967.CrossRefPubMedPubMedCentral

13.

Luo Y, Pan Q, Zhang W. IgG4-related disease revealed by (68)Ga-FAPI and (18)F-FDG PET/CT. Eur J Nucl Med Mol Imaging. 2019;46(12):2625–6. https://doi.org/10.1007/s00259-019-04478-2.CrossRefPubMed

14.

Pan Q, Luo Y, Zhang W. Recurrent immunoglobulin G4-related disease shown on 18F-FDG and 68Ga-FAPI PET/CT. Clin Nucl Med. 2020. https://doi.org/10.1097/RLU.0000000000002919.

15.

Spadafora M, Pace L, Evangelista L, Mansi L, Del Prete F, Saladini G, et al. Risk-related (18)F-FDG PET/CT and new diagnostic strategies in patients with solitary pulmonary nodule: the ITALIAN multicenter trial. Eur J Nucl Med Mol Imaging. 2018;45(11):1908–14. https://doi.org/10.1007/s00259-018-4043-y.CrossRefPubMed

16.

Redondo-Cerezo E, Martinez-Cara JG, Jimenez-Rosales R, Valverde-Lopez F, Caballero-Mateos A, Jervez-Puente P, et al. Endoscopic ultrasound in gastric cancer staging before and after neoadjuvant chemotherapy. A comparison with PET-CT in a clinical series. United European Gastroenterol J. 2017;5(5):641–7. https://doi.org/10.1177/2050640616684697.CrossRefPubMed

17.

Jiang C, Chen Y, Zhu Y, Xu Y. Systematic review and meta-analysis of the accuracy of 18F-FDG PET/CT for detection of regional lymph node metastasis in esophageal squamous cell carcinoma. J Thoracic Dis. 2018;10(11):6066–76.CrossRef

18.

Jadvar H. Is there use for FDG-PET in prostate cancer? Semin Nucl Med. 2016;46(6):502–6. https://doi.org/10.1053/j.semnuclmed.2016.07.004.CrossRefPubMedPubMedCentral

19.

Findlay JM, Antonowicz S, Segaran A, El Kafsi J, Zhang A, Bradley KM, et al. Routinely staging gastric cancer with (18)F-FDG PET-CT detects additional metastases and predicts early recurrence and death after surgery. Eur Radiol. 2019;29(5):2490–8. https://doi.org/10.1007/s00330-018-5904-2.CrossRefPubMedPubMedCentral

20.

Sivesgaard K, Larsen LP, Sorensen M, Kramer S, Schlander S, Amanavicius N, et al. Diagnostic accuracy of CE-CT, MRI and FDG PET/CT for detecting colorectal cancer liver metastases in patients considered eligible for hepatic resection and/or local ablation. Eur Radiol. 2018;28(11):4735–47. https://doi.org/10.1007/s00330-018-5469-0.CrossRefPubMed

21.

Coccolini F, Gheza F, Lotti M, Virzi S, Iusco D, Ghermandi C, et al. Peritoneal carcinomatosis. World J Gastroenterol. 2013;19(41):6979–94. https://doi.org/10.3748/wjg.v19.i41.6979.CrossRefPubMedPubMedCentral

22.

Shimada H, Okazumi S, Koyama M, Murakami K. Japanese Gastric Cancer Association Task Force for Research Promotion: clinical utility of ¹⁸F-fluoro-2-deoxyglucose positron emission tomography in gastric cancer. A systematic review of the literature. Gastric Cancer. 2011;14(1):13–21. https://doi.org/10.1007/s10120-011-0017-5.CrossRefPubMed

23.

Rubini G, Altini C, Notaristefano A, Merenda N, Rubini D, Ianora AA, et al. Role of 18F-FDG PET/CT in diagnosing peritoneal carcinomatosis in the restaging of patient with ovarian cancer as compared to contrast enhanced CT and tumor marker Ca-125. Rev Esp Med Nucl Imagen Mol. 2014;33(1):22–7. https://doi.org/10.1016/j.remn.2013.06.008.CrossRefPubMed

24.

Lindner T, Loktev A, Giesel F, Kratochwil C, Altmann A, Haberkorn U. Targeting of activated fibroblasts for imaging and therapy. EJNMMI Radiopharm Chem. 2019;4(1):16. https://doi.org/10.1186/s41181-019-0069-0.CrossRefPubMedPubMedCentral

25.

Rohrich M, Loktev A, Wefers AK, Altmann A, Paech D, Adeberg S, et al. IDH-wildtype glioblastomas and grade III/IV IDH-mutant gliomas show elevated tracer uptake in fibroblast activation protein-specific PET/CT. Eur J Nucl Med Mol Imaging. 2019;46(12):2569–80. https://doi.org/10.1007/s00259-019-04444-y.CrossRefPubMed

26.

Glaudemans AW, Enting RH, Heesters MA, Dierckx RA, van Rheenen RW, Walenkamp AM, et al. Value of 11C-methionine PET in imaging brain tumours and metastases. Eur J Nucl Med Mol Imaging. 2013;40(4):615–35. https://doi.org/10.1007/s00259-012-2295-5.CrossRefPubMed

27.

Chen W, Cloughesy T, Kamdar N, Satyamurthy N, Bergsneider M, Liau L, et al. Imaging proliferation in brain tumors with 18F-FLT PET: comparison with 18F-FDG. J Nucl Med. 2005;46(6):945–52.PubMed

28.

Afshar-Oromieh A, Hetzheim H, Kubler W, Kratochwil C, Giesel FL, Hope TA, et al. Radiation dosimetry of (68)Ga-PSMA-11 (HBED-CC) and preliminary evaluation of optimal imaging timing. Eur J Nucl Med Mol Imaging. 2016;43(9):1611–20. https://doi.org/10.1007/s00259-016-3419-0.CrossRefPubMed

29.

Sandstrom M, Velikyan I, Garske-Roman U, Sorensen J, Eriksson B, Granberg D, et al. Comparative biodistribution and radiation dosimetry of 68Ga-DOTATOC and 68Ga-DOTATATE in patients with neuroendocrine tumors. J Nucl Med. 2013;54(10):1755–9. https://doi.org/10.2967/jnumed.113.120600.CrossRefPubMed

30.

Meyer C, Dahlbom M, Lindner T, Vauclin S, Mona C, Slavik R, et al. Radiation dosimetry and biodistribution of (68)Ga-FAPI-46 PET imaging in cancer patients. J Nucl Med. 2019. https://doi.org/10.2967/jnumed.119.236786.

Title: Comparison of [68Ga]Ga-DOTA-FAPI-04 and [18F] FDG PET/CT for the diagnosis of primary and metastatic lesions in patients with various types of cancer
Authors: Haojun Chen
Yizhen Pang
Jingxun Wu
Liang Zhao
Bing Hao
Jing Wu
Jihong Wei
Siming Wu
Long Zhao
Zuoming Luo
Xuehua Lin
Chengrong Xie
Long Sun
Qin Lin
Hua Wu
Publication date: 01-07-2020
Publisher: Springer Berlin Heidelberg
Keyword: Metastasis
Published in: European Journal of Nuclear Medicine and Molecular Imaging / Issue 8/2020
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-020-04769-z

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Comparison of [⁶⁸Ga]Ga-DOTA-FAPI-04 and [¹⁸F] FDG PET/CT for the diagnosis of primary and metastatic lesions in patients with various types of cancer

Abstract

Purpose

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 8/2020

Reply to: Clinical brain PET research must embrace multi-centre collaboration and data sharing or risk its demise: emphasis should also be placed on the critical role of image analysis schemes

Staging and quantification of florbetaben PET images using machine learning: impact of predicted regional cortical tracer uptake and amyloid stage on clinical outcomes

When nuclear medicine radiological protection meets biological COVID-19 protection

Key elements of preparedness for pandemic coronavirus disease 2019 (COVID-19) in nuclear medicine units

Binding of [18F]AV1451 in post mortem brain slices of semantic variant primary progressive aphasia patients